title: In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.
abstract: Mutations affecting the expression of the Janus family kinase JAK3 were recently shown to be responsible for autosomal recessive severe combined immunodeficiency (SCID). JAK3-deficient patients present with a clinical phenotype virtually indistinguishable from boys affected by X-linked SCID, a disease caused by genetic defects of the common gamma chain (gamma c) that is a shared component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15. The specific interaction of JAK3 and gamma c represents the biochemical basis for the similarities between these two immunodeficiencies. Both forms of SCID are characterized by recurrent, severe infections leading to death in infancy unless successfully treated by allogeneic bone marrow transplantation. Because of the potentially lethal complications associated with allogeneic bone marrow transplantation and the frequent lack of suitable marrow donors, the development of alternative forms of therapy is highly desirable. To this end, we investigated a retroviral-mediated gene correction approach for JAK3-deficiency. A vector carrying a copy of JAK3 cDNA was constructed and used to transduce B cell lines derived from patients with JAK3-deficient SCID. We demonstrate restoration of JAK3 expression and phosphorylation upon IL-2 and IL-4 stimulation. Furthermore, patients' cells transduced with JAK3 acquired the ability to proliferate normally in response to IL-2. These data indicate that the biological defects of JAK3-deficient cells can be efficiently corrected in vitro by retroviral-mediated gene transfer, thus providing the basis for future investigation of gene therapy as treatment for JAK3-deficient SCID.
authors.affiliation: Clinical Gene Therapy Branch, National Center for Human Genome Research, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: F
authors.initials: F
authors.lastname: Candotti
authors.forename: S A
authors.initials: SA
authors.lastname: Oakes
authors.forename: J A
authors.initials: JA
authors.lastname: Johnston
authors.forename: L D
authors.initials: LD
authors.lastname: Notarangelo
authors.forename: J J
authors.initials: JJ
authors.lastname: O'Shea
authors.forename: R M
authors.initials: RM
authors.lastname: Blaese
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D015153:Blotting, Western; D002478:Cells, Cultured; D002648:Child; D003001:Cloning, Molecular; D003241:Consanguinity; D005808:Genes, Recessive; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D053616:Janus Kinase 3; D008213:Lymphocyte Activation / Q000187:drug effects; D046911:Macromolecular Substances; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics*; D018123:Receptors, Interleukin / Q000235:genetics*; D011994:Recombinant Proteins / Q000096:biosynthesis; D012190:Retroviridae; D016511:Severe Combined Immunodeficiency / Q000201:enzymology / Q000235:genetics* / Q000628:therapy*; D014162:Transfection; D014960:X Chromosome
chemical_list: D007376:Interleukin-2; D046911:Macromolecular Substances; D018123:Receptors, Interleukin; D011994:Recombinant Proteins; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3